April 28, 2015
Cold Spring Harbor Perspectives in Medicine
By Amanda K. Murphy, Ph.D.; Thomas L. Irving; *Stacy D. Lewis
The AIA’s most publicized change transforms the United States from a “first-to-invent” system to a “first-inventorto- file” regime, bringing U.S. patent law more in line with the patent systems of nearly every other industrialized country in the world. This new system requires small companies and independent inventors to toe the line against larger competitors in what many have called a “race to the patent office.” But a closer look at the AIA reveals several opportunities for smaller entities that may even the playing field, particularly for innovators in the biotech sector. In this article, Finnegan attorneys Amanda K. Murphy, Michael A. Stramiello, Jonathan R.K. Stroud, and Thomas L. Irving address changes that the AIA brings to U.S. patent law, keeping an eye toward issues relevant to biotech companies.
*Stacy Lewis is a law clerk at Finnegan.
June 10-12, 2024
San Francisco
10th Annual Georgia Asian Pacific American Bar Association Gala
May 29, 2024
Atlanta
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.